Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Which stocks will surge next?
Unlock AI-picked Stocks
SpectraCure AB (SPEC)
Add to/Remove from a Portfolio
Add to Watchlist
2.870
+0.145
+5.32%
- Volume: 97,388
- Bid/Ask: 2.870 / 2.870
- Day's Range: 2.725 - 3.000
SpectraCure
2.870
+0.145
+5.32%
- Discussions
- Recent Sentiments
- User Rankings
SPEC User Rankings
Bellow, users are ranked according to the performance of their sentiments for the SpectraCure AB stock.
| Rank | Username | Total | Closed | Winning | Win % | Chg. % |
|---|---|---|---|---|---|---|
| 1 | Fredrik Isacsson | 2 | 2 | 1 | 50 | +92.04% |
| 2 | Johan Hallgren | 4 | 4 | 2 | 50 | +82.86% |
| 3 | Jonas Deckeman | 4 | 4 | 4 | 100 | +58.29% |
| 4 | tommi penttila | 1 | 1 | 1 | 100 | +57.98% |
| 5 | Weimer Andersson | 1 | 1 | 1 | 100 | +53.06% |
| 6 | Lucas Enblom | 1 | 1 | 1 | 100 | +52.81% |
| 7 | Marcus Kartberg | 1 | 1 | 1 | 100 | +47.88% |
| 8 | Sami Lohtander | 3 | 3 | 2 | 66.67 | +43.9% |
| 9 | Arttu Kyner | 1 | 1 | 1 | 100 | +35.17% |
| 10 | Jonas Eriksson | 1 | 1 | 1 | 100 | +34.97% |
| 11 | Martin Lundgren | 1 | 1 | 1 | 100 | +30.63% |
| 12 | Daniel Norén | 1 | 1 | 1 | 100 | +30.24% |
| 13 | Kimpa Seppälä | 4 | 4 | 2 | 50 | +28.19% |
| 14 | Simon Jonsson | 1 | 1 | 1 | 100 | +27.58% |
| 15 | Simon Byström | 2 | 2 | 1 | 50 | +25.8% |
| 16 | Jo Hö | 1 | 1 | 1 | 100 | +25.08% |
| 17 | Rickard Lindqvist | 1 | 1 | 1 | 100 | +23.7% |
| 18 | Sanin Bilalovic | 1 | 1 | 1 | 100 | +23.39% |
| 19 | Tony Simonsson | 1 | 1 | 1 | 100 | +23.3% |
| 20 | Fredrika Stiller | 1 | 1 | 1 | 100 | +22.78% |
| 21 | Fredrik Öfverberg | 1 | 1 | 1 | 100 | +21.48% |
| 22 | Nicklas Wåhlström | 1 | 1 | 1 | 100 | +20.09% |
| 23 | Pier Zigante | 3 | 3 | 1 | 33.33 | +19.6% |
| 24 | Perry Norling | 1 | 1 | 1 | 100 | +16.25% |
| 25 | Heikki Nurkkala | 1 | 1 | 1 | 100 | +13.7% |
| 26 | Alexander Örn | 2 | 2 | 1 | 50 | +13.5% |
| 27 | Daniel Nattfalk | 1 | 1 | 1 | 100 | +13.21% |
| 28 | Michael Forsell | 1 | 1 | 1 | 100 | +12.5% |
| 29 | Massimo Moioli | 7 | 7 | 4 | 57.14 | +12.16% |
| 30 | Philip volny | 3 | 3 | 1 | 33.33 | +8.47% |
| 31 | Isak Karlsson | 1 | 1 | 1 | 100 | +8.25% |
| 32 | Christian Lönnegren | 2 | 2 | 1 | 50 | +8.02% |
| 33 | Magnus Gunnarsson | 1 | 1 | 1 | 100 | +6.69% |
| 34 | Ludvig Björkqvist | 1 | 1 | 1 | 100 | +6.26% |
| 35 | Filip Session | 4 | 4 | 2 | 50 | +5.04% |
| 36 | Simon Otku | 1 | 1 | 1 | 100 | +4.9% |
| 37 | Erik Svensson | 1 | 1 | 1 | 100 | +4.51% |
| 38 | Tomas Johansson | 9 | 9 | 6 | 66.67 | +3.67% |
| 39 | Carin Gustavsson | 2 | 2 | 1 | 50 | +2.93% |
| 40 | Carl Angervall | 1 | 1 | 1 | 100 | +2.77% |
| 41 | Viktor Lång | 1 | 1 | 1 | 100 | +1.51% |
| 42 | Sorosh Farahmand | 1 | 1 | 1 | 100 | +1.31% |
| 43 | Dag Sjölin | 2 | 1 | 1 | 100 | +1.17% |
| 44 | Jonatan Andersson | 1 | 1 | 1 | 100 | +0.25% |
| 45 | Rasmus Ekelöf | 1 | 1 | 0 | 0 | 0% |
| 46 | Freddy Gustavsson | 1 | 1 | 0 | 0 | 0% |
| 47 | Alexander Esbjörnsson | 1 | 1 | 0 | 0 | 0% |
| 48 | Peter Andersson | 1 | 1 | 0 | 0 | 0% |
| 49 | Eh Sa | 1 | 1 | 0 | 0 | 0% |
| 50 | Daniel Byrsten | 1 | 1 | 0 | 0 | 0% |
Write your thoughts about SpectraCure AB
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review